Neuraly Announces Topline Results from Phase 2 Trial of NLY01 in Parkinson’s Disease

Neuraly, a clinical-stage biotechnology company pioneering development of disease-modifying agents for neurodegenerative disorders, today announced topline results from the Phase 2 trial with NLY01 in patients with early, untreated Parkinson’s disease (PD). The primary endpoint, change from baseline to Week 36 in the sum of MDS-UPDRS Parts II (Motor Experiences of Daily Living) and III (Motor Examination) after 36 weeks of NLY01 treatment, compared to placebo, did not reach statistical significance. NLY01 was safe and well tolerated. The effect was statistically significant, dose-related, and appeared persistent over eight weeks after treatment was discontinued. These results suggest slower disease progression in NLY01-treated subjects compared to placebo-treated subjects in this age group. Detailed data will be presented at future medical meetings. Read more >>